AXS Offset Delivery Assist Catheter

K163259 · Stryker Neurovascular · DQY · Jul 28, 2017 · Cardiovascular

Device Facts

Record IDK163259
Device NameAXS Offset Delivery Assist Catheter
ApplicantStryker Neurovascular
Product CodeDQY · Cardiovascular
Decision DateJul 28, 2017
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 870.1250
Device ClassClass 2

Intended Use

The AXS Offset Delivery Assist Catheter is intended to assist in the delivery of interventional devices, such as distal access catheters, in the neurovasculature.

Device Story

The AXS Offset Delivery Assist Catheter is a sterile, single-lumen, variable-stiffness catheter used to facilitate the insertion and delivery of interventional devices (e.g., distal access catheters) into neurovascular blood vessels. It is an over-the-wire device used with a steerable guidewire. The catheter features a hydrophilic coating to reduce friction, a radiopaque marker for fluoroscopic visualization, and a proximal luer hub for saline flushing. During use, the catheter acts as a transition, reducing the gap between the guidewire and the distal access catheter (DAC) to provide a smooth system profile. It is operated by a physician in a clinical setting. The device allows for continuous saline flush through the DAC while in place. By facilitating smoother navigation and delivery of interventional tools, the device helps physicians access target sites in the neurovasculature, potentially improving procedural efficiency and patient outcomes.

Clinical Evidence

Bench testing only. Testing included dimensional verification, friction force, distal tip buckling, tensile strength, liquid/air leakage, particle analysis, coating integrity, trackability, flow rate, kink radius, torsional resistance, and biocompatibility (ISO 10993). Simulated use in a neurovascular tortuosity model confirmed device trackability and integrity. No clinical data was required or presented.

Technological Characteristics

Single-lumen, variable-stiffness catheter; hydrophilic coating; radiopaque distal marker; luer hub. Materials are similar to predicate devices. Sterilization via 100% Ethylene Oxide. Dimensions: 150cm effective length, 0.021in ID, 2.7F distal OD. No software or electronic components.

Indications for Use

Indicated for assisting in the delivery of interventional devices, such as distal access catheters, within the neurovasculature.

Regulatory Classification

Identification

A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, with flowing lines connecting them. Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 July 28, 2017 Stryker Neurovascular Angelica Beckmann Director, Regulatory Affairs 47900 Bayside Parkway Fremont, California 94538 Re: K163259 Trade/Device Name: AXS Offset Delivery Assist Catheter Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous Catheter Regulatory Class: Class II Product Code: DQY Dated: June 29, 2017 Received: June 30, 2017 Dear Ms. Beckmann: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {1}------------------------------------------------ If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Sincerely, for Carlos L. Peña, PhD, MS Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ ## Please wait... If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document. You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download. For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader. Windows is either a registered trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries. {3}------------------------------------------------ ### 510(k) Summary | Device Trade Name: | AXS Offset Delivery Assist Catheter | | | | | |----------------------|----------------------------------------------------------------------------------------------------------------------------------------|--|--|--|--| | Common Name: | Percutaneous Catheter | | | | | | Classification Name: | Percutaneous Catheter, 21CFR 870.1250 Class II | | | | | | Product Code: | DQY | | | | | | Submitter: | Stryker Neurovascular<br>47900 Bayside Parkway<br>Fremont, CA 94538<br>Facility Registration #2954917 | | | | | | Contact: | Angelica Beckmann<br>Director, Regulatory Affairs<br>Tel 510 - 413-2900<br>Fax 510 - 413-2588 | | | | | | Date Prepared: | July 27, 2017 | | | | | | Predicate Device: | Primary Predicate Device K113778<br>(clearance granted<br>April 20, 2012) Excelsior XT-27 Microcatheter Reference Predicate Device | | | | | | K122576 | Transform Occlusion Balloon Catheter | |-----------------------------------------|--------------------------------------| | (clearance granted<br>January 11, 2013) | | {4}------------------------------------------------ Premarket Notification, Traditional 510(k) AXS Offset Delivery Assist Catheter ### Device Description The AXS Offset Delivery Assist Catheter ("AXS Offset") is a sterile, single lumen, variable stiffness catheter designed for use in facilitating the insertion and delivery of appropriately sized interventional devices, such as distal access catheters (DAC), into a selected blood vessel in the neurovascular system. The AXS Offset catheter, when used in conjunction with an appropriately sized steerable guidewire and DAC, provides a smooth interventional device system profile. The distal outer diameter (OD) of the AXS Offset catheter gradually increases from 0.036in at the RO Marker to 0.050in, 2 cm proximal to the RO marker. The bulb section with a 0.050in OD is maintained for 28 cm. then gradually decreases towards the proximal section. The overall distal profile of the AXS Offset catheter acts as a smooth transition and reduces the gap between the outer diameter of a steerable guidewire and inner diameter of a DAC while allowing for continuous saline flush through the DAC. The catheter shaft has a hydrophilic coating to reduce friction during use. The catheter includes a radiopaque marker on the distal end for angiographic visualization and a luer hub on the proximal end allowing attachments for flushing. ### Accessories No accessories are provided with the AXS Offset. ### Indications for Use The Indications for Use are similar to the predicate devices and are as follows: The AXS Offset Delivery Assist Catheter is intended to assist in the delivery of interventional devices, such as distal access catheters, in the neurovasculature. ### Technological Characteristics and Product Feature Comparison The subject device, AXS Offset Delivery Assist Catheter is substantially equivalent to the predicate devices in terms of: - indications for use ● - fundamental scientific technology - fundamental design ● - materials and processes for packaging and sterilization of devices ● A tabular comparison of the specific technological characteristics between the predicate devices and subject device is provided below. {5}------------------------------------------------ | Characteristics | Subject Device | Primary Predicate Device | Reference Predicate Device | |-------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Device Name | AXS Offset Delivery Assist<br>Catheter | Excelsior® XT-27<br>Microcatheter | Transform Occlusion Balloon<br>Catheter | | 510(k) | Current Notification | K113778 | K122576 | | Device<br>Classification/<br>Product Code | Class II/ DQY<br>(Percutaneous catheters) | Class II/ DQY<br>(Percutaneous catheters) | Class II/MJN<br>(Temporary Intravascular<br>Occluding Catheter) | | Intended Use | The AXS Offset Delivery<br>Assist Catheter is intended to<br>assist in the delivery of<br>interventional devices, such<br>as distal access catheters, in<br>the neurovasculature. | Stryker Neurovascular<br>Excelsior XT-27<br>Microcatheter is intended to<br>assist in the delivery of<br>diagnostic agents (such as<br>contrast media), therapeutic<br>agents, and non-liquid<br>interventional devices (such<br>as stents) that are indicated<br>for use in the<br>neurovasculature and with a<br>catheter of 0.027 inches in<br>inner diameter. | The Stryker Neurovascular<br>TransForm Occlusion Balloon<br>Catheters are indicated for use<br>in the neuro and peripheral<br>vasculature to temporarily stop<br>or control blood flow and for<br>balloon assisted embolization of<br>intracranial aneurysms. | | Characteristics | Subject Device | Primary Predicate Device | Reference Predicate Device | | Device Name | AXS Offset Delivery Assist<br>Catheter | Excelsior® XT-27<br>Microcatheter | Transform Occlusion Balloon<br>Catheter | | 510(k) | Current Notification | K113778 | K122576 | | Principle of<br>Operations | Delivery Assist Catheters are<br>used to access and navigate<br>the vasculature as well as to<br>deliver Distal Access<br>Catheters (DAC). The AXS<br>Offset Delivery Assist<br>Catheter is inserted through a<br>DAC and guided through the<br>vasculature with the aid of a<br>guidewire (over-the-wire<br>catheter). | Microcatheters are used to<br>access and navigate the<br>vasculature as well as to<br>deliver diagnostic therapeutic<br>agents, and/or interventional<br>devices. Typically these<br>vascular microcatheters are<br>inserted with a guide catheter<br>and guided through the<br>vasculature with the aid of a<br>guidewire (over-the-wire<br>microcatheters). | The device is advanced into the<br>vasculature using an 0.014 inch<br>OD guidewire and inside a<br>5F or larger guide catheter<br>placed in the femoral artery.<br>The radiopaque markers are<br>observed under fluoroscopy as a<br>guide to positioning the balloon<br>at the intended treatment site.<br>Once at the treatment site, the<br>guidewire is used to seal the<br>distal end of the catheter<br>allowing inflation of the<br>balloon. A mixture of saline and<br>contrast is injected into the<br>catheter lumen to inflate the<br>balloon to its nominal volume;<br>fluoroscopy is used to ensure<br>proper positioning. Once<br>beyond the distal tip of the<br>catheter, the guidewire can be<br>moved distally or proximally<br>while maintaining balloon<br>inflation. | ### Product Feature Comparison of Subject Device with Predicate Devices (K113778, K122576) {6}------------------------------------------------ Premarket Notification, Traditional 510(k) AXS Offset Delivery Assist Catheter {7}------------------------------------------------ Premarket Notification, Traditional 510(k) AXS Offset Delivery Assist Catheter | Characteristics | Subject Device | Primary Predicate Device | Reference Predicate Device | |-------------------------|----------------------------|--------------------------|-----------------------------| | Device Name | AXS Offset Delivery Assist | Excelsior ® XT-27 | Transform Occlusion Balloon | | | Catheter | Microcatheter | Catheter | | 510(k) | Current Notification | K113778 | K122576 | | Sterilization<br>Method | Ethylene Oxide | Ethylene Oxide | Ethylene Oxide | ### Design Comparison of Subject Device with Predicate Devices (K113778, K122576) | | Proposed Device | Predicate Device | Predicate Device | Rationale for difference<br>(if applicable) | |-----------------------------------------------------|----------------------------------------|------------------------------------|-----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Feature | AXS Offset Delivery<br>Assist Catheter | Excelsior® XT-27<br>Microcatheter | Transform Occlusion<br>Balloon Catheter | | | | Current Notification | K113778 | K122576 | | | Proximal OD | 3.0F (1.0mm) | 2.9F (0.97mm) | 2.8F (0.95mm) | No significant difference | | Distal OD | 2.7F (0.91mm) | 2.7F (0.91mm) | 2.7F (0.95mm) | N/A - Same as primary predicate | | Feature | Proposed Device | Predicate Device | Predicate Device | Rationale for difference<br>(if applicable) | | | AXS Offset Delivery<br>Assist Catheter | Excelsior® XT-27<br>Microcatheter | Transform Occlusion<br>Balloon Catheter | | | | Current Notification | K113778 | K122576 | | | Maximum<br>Catheter<br>Diameter<br>(distal section) | 3.8F (1.27mm)<br>*reference figure | 2.7F (0.91mm)<br>*reference figure | 3.8F(1.27mm)<br>*reference figure | The AXS Offset outside diameter<br>is similar to the predicate devices.<br>AXS Offset has the same<br>materials as the predicate as seen<br>in table 13-7. Thrombogenicity<br>testing demonstrated no risk of<br>thrombosis for the AXS Offset<br>Catheter like the predicate device.<br>Biocompatibility testing was also<br>completed to show no increased<br>risk compared to the predicate<br>devices. The bench testing was<br>performed in a neurovascular<br>tortuosity model to confirm the<br>continuous flush solution will be<br>adequately maintained between<br>the AXS Offset and DAC during<br>use. | | ID | 0.53mm (.021in) | 0.69mm (0.027in) | 0.31mm (.0124in) | AXS Offset ID of .021" is within<br>the ranges of both predicate<br>devices. .021" ID is a common<br>size for a catheter of this length<br>and OD. | | Feature | Proposed Device | Predicate Device | Predicate Device | Rationale for difference<br>(if applicable) | | | AXS Offset Delivery<br>Assist Catheter | Excelsior® XT-27<br>Microcatheter | Transform Occlusion<br>Balloon Catheter | | | | Current Notification | K113778 | K122576 | | | Hydrophilic<br>Coating<br>Length | 80cm | 80cm | 80cm - 83cm | N/A - Same as primary predicate | | Effective<br>Length | 150cm | 135 cm<br>150 cm | 150 cm - 153cm | N/A - Same as primary predicate | | Tip Length | 2cm | 6 cm<br>18 cm | 1cm - 3cm | AXS Offset tip length of 2cm is<br>similar to the predicate devices.<br>The tip length is used to describe<br>the section distal of the bulb<br>feature of the AXS Offset but the<br>tip length does not significantly<br>affect the product performance.<br>The materials of the tip are more<br>impactful to product<br>performance. Both AXS Offset<br>and Excelsior XT-27 have the<br>same distal tip materials and<br>distal OD and thus have similar<br>performance. | | Tip Shape | Straight | Straight | Straight | N/A - Same as primary predicate | {8}------------------------------------------------ Premarket Notification, Traditional 510(k) AXS Offset Delivery Assist Catheter {9}------------------------------------------------ Premarket Notification, Traditional 510(k) AXS Offset Delivery Assist Catheter {10}------------------------------------------------ ### Risk Assessment Risk assessment of the AXS Offset Delivery Assist Catheter has been conducted in accordance with EN ISO 14971 and Stryker Neurovascular's risk management procedures. Stryker Neurovascular has determined that the AXS Offset Delivery Assist Catheter raises no new safety or effectiveness issues. Results of verification and validation testing have demonstrated the subject device is substantially equivalent to the predicate devices. ### Testing Summary The results of verification and validation testing conducted on the subject device demonstrate that it performs as designed, and is suitable for its intended use. Specifically, the following tests were performed on the subject device: {11}------------------------------------------------ # Stryker Neurovascular Premarket Notification, Traditional 510(k) AXS Offset Delivery Assist Catheter | Test | Test Method | Results | |--------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Dimensional<br>Verification | Verified dimensions<br>using specified<br>measurement tool | Dimensional verification meets acceptance criteria for catheter<br>effective length, uncoated length, distal tip outer diameter, and<br>inner diameter | | | | Substantial Equivalence: XT-27 and AXS Offset meet the same<br>dimensional effective length, uncoated length, and distal tip outer<br>diameter acceptance criteria | | | | For inner diameter, XT-27 and AXS Offset meet their respective<br>dimensional inner diameter acceptance criteria. The inner lumens<br>of both devices are compatible with standard neurovascular guide<br>wires. | | Dimensional:<br>Maximum Outer<br>Diameter | Verified dimensions<br>using specified<br>measurement tool | Dimensional verification meets acceptance criteria for maximum<br>outer diameter | | | | Substantial Equivalence: XT-27 and AXS Offset meet their<br>respective dimensional (maximum outer diameter) acceptance<br>criteria. The differences in the max OD between the XT27 and<br>AXS Offset are related to the differences in the indications for use<br>of both devices. | | Friction Force | Measured friction<br>force to determine<br>the lubricity and<br>durability of the<br>coating on a catheter<br>shaft using a friction<br>tester | Friction force meets acceptance criteria<br>Substantial Equivalence: XT-27 and AXS Offset meet the same<br>friction force acceptance criteria. | | Catheter Distal Tip<br>Buckling | Measured force<br>required to buckle<br>distal shaft using tip<br>buckling tester | Distal tip buckling meets acceptance criteria<br>Substantial Equivalence: XT-27 and AXS Offset meet the same<br>distal tip buckling acceptance criteria. | | Catheter Tensile<br>Strength | Measured catheter<br>shaft peak tensile<br>strength using Instron<br>tensile tester per test<br>guideline, ISO10555-<br>1 Peak Tensile Force | Catheter tensile strength meets acceptance criteria<br>Substantial Equivalence: XT-27 and AXS Offset meet the same<br>catheter tensile strength acceptance criteria. | | Catheter Hub Tensile<br>Strength | Measured catheter<br>shaft to hub tensile<br>junction strength<br>using Instron tensile<br>tester per test<br>guideline, ISO10555-<br>1 Peak Tensile Force | Catheter hub tensile strength meets acceptance criteria<br>Substantial Equivalence: XT-27, Transform, and AXS Offset meet<br>the same catheter hub tensile strength acceptance criteria. | | Liquid-Leakage | Determined whether<br>liquid leaks from the<br>catheter under<br>pressure per EN ISO<br>10555-<br>1:2013 and EN<br>1707:1996 | Liquid-leakage meets acceptance criteria<br>Substantial Equivalence: XT-27, Transform, and AXS Offset meet<br>the same liquid-leakage acceptance criteria. | | Air Aspiration Leakage | Determined whether<br>air leaks into the hub<br>assembly during<br>aspiration per EN<br>ISO 10555-1:2013<br>and EN 1707:1996. | Air aspiration leakage meets acceptance criteria<br>Substantial Equivalence: XT-27, Transform, and AXS Offset meet<br>the same air aspiration leakage acceptance criteria. | | Particle Analysis for<br>Catheters | Performed simulated<br>use procedures for <i>in vitro</i> acute phase<br>particulate<br>characterization<br>using a particle<br>counter | Particle analysis characterization testing completed and is for<br>reference only.<br>Particulate count results for the AXS Offset in all particulate size<br>ranges are similar or lower than the predicate device XT-27 | | Coating Integrity | Checked visual<br>condition of catheter<br>and noted<br>observations of the<br>catheter coatings<br>before and after<br>simulated use | Neither the Baseline test articles nor the Post-tracking test articles<br>exhibited any delamination at coating edges (either proximal or<br>distal). The Baseline test articles did not exhibit any coating defects<br>(voids or scratches). The post tracking devices exhibited no<br>anomolies along the 80cm coating length. When considered in<br>conjunction with coating lubricity and durability results and the<br>particulate generation results, the coating functions as intended and<br>has exhibited appropriate integrity (via visual assessment) post<br>simulated use. | | Track and Advance<br>Force | Measured the<br>advance and<br>retraction force in<br>simulated use<br>conditions from the<br>petrous segment of<br>the internal carotid<br>artery to the M1 of<br>the middle cerebral<br>artery. | AXS Offset catheter advance and retraction force in simulated use<br>testing has been demonstrated to be equivalent or lower than the<br>predicate XT-27. | | Flow Rate | Measured flow rate<br>for saline infusion<br>through a Distal<br>Access Catheter<br>(DAC) when the<br>AXS Offset catheter<br>was positioned within<br>the lumen of the<br>DAC. | Testing has demonstrated a continuous positive displacement of<br>saline fluid through the lumen of the DAC with the AXS Offset<br>catheter positioned in the DAC lumen. Testing was conducted in a<br>simulated neurovascular tortuosity model. | | Catheter Kink Radius | Measured the kink<br>radius of catheter<br>using a fixture | Catheter kink radius meets acceptance criteria<br>Substantial Equivalence: XT-27 and AXS Offset meet the same<br>kink radius acceptance criteria. | | Catheter Torsional<br>Resistance | Measured the<br>strength of catheter<br>shaft while it rotates<br>in a clinically<br>relevant vascular path<br>to determine how<br>many turns (360-<br>degree rotations) are<br>required to break the<br>shaft | Catheter torsional resistance meets acceptance criteria<br>Substantial Equivalence: XT-27 and AXS Offset meet the same<br>torsional resistance acceptance criteria. | | | | | | Visual Standards | Visually checked<br>catheter length for<br>extraneous matter<br>and process defects.<br>Additionally,<br>checked for smooth<br>and rounded distal tip<br>using specified<br>measurement tools | Visual standards meet acceptance criteria for catheter length being<br>free from extraneous matter and process defects and for catheter<br>distal tip being smooth and rounded.<br>Substantial Equivalence: XT-27 and AXS Offset meet the same<br>visual standards acceptance criteria. | | Visual and<br>Dimensional Integrity<br>– Chemical<br>Compatibility | Performed visual,<br>dimensional, and<br>mandrel passage<br>examinations to<br>determine visual and<br>dimensional integrity<br>of the hub, inner<br>lumen, and outer<br>distal region of<br>catheter after<br>exposure to saline,<br>non-ionic contrast,<br>and ionic contrast. | Visual and Dimensional Integrity - Chemical Compatibility meets<br>acceptance criteria<br>Substantial Equivalence: XT-27 and AXS Offset meet the same<br>visual and dimensional integrity - chemical compatibility<br>acceptance criteria. | | Device Trackability | The device was<br>advanced to the M1<br>using standard access<br>methods similar to<br>XT-27. In order to<br>meet acceptance<br>criteria, the evaluating<br>physician/s must state<br>that the test articles<br>can advance to the<br>M1 in conjunction<br>with the intermediate<br>catheter in the bench<br>model. | Device Trackability meets acceptance criteria<br>Substantial equivalence: XT-27 and AXS Offset meet the same<br>device trackability acceptance criteria.<br>After advancing the Test article with the intermediate catheters in<br>the model, the physicians confirmed that all of the test articles were<br>able to advance to the M1 using standard access methods similar to<br>XT-27. | | Device - Durability<br>and Integrity | The integrity of the<br>device was assessed<br>throughout the<br>duration of the<br>procedure using the<br>bench model. In order<br>to meet acceptance<br>criteria, the evaluating<br>physician/s must state<br>that all test articles<br>maintain their<br>integrity throughout<br>procedure. | Device Durability and Integrity meets acceptance criteria<br>The evaluating physicians confirmed that the all test articles<br>maintained their integrity throughout procedure.<br>Substantial Equivalence: XT-27 and AXS Offset meet the device-<br>durability and integrity acceptance criteria. | | Guidewire<br>Compatibility | Guidewires up to<br>0.018in OD were<br>allowed to advance<br>and withdraw from<br>the AXS Offset<br>device during the<br>procedure using the<br>bench model. In | Guidewire Compatibility meets acceptance criteria<br>The evaluating physicians confirmed that all test articles allowed<br>smooth advancement and withdrawal of standard guidewires up to<br>0.018in OD. | | | order to meet<br>acceptance criteria,<br>the evaluating<br>physician/s must state<br>that all test articles<br>allow smooth<br>advancement and<br>withdrawal of<br>standard guidewires<br>up to 0.018in OD. | Substantial Equivalence: XT-27 and AXS Offset meet the same<br>guidewire compatibility acceptance criteria. | | Labelling requirements | The physician read<br>the DFU and labeling.<br>In order to meet<br>acceptance criteria,<br>the evaluating<br>physician/s must state<br>that DFU and labeling<br>of all test articles<br>clearly identify the<br>product and provide<br>information adequate<br>to ensure the safe use<br>of the device. | Labelling Requirements meet acceptance criteria<br>The evaluating physicians confirmed that the DFU and labeling of<br>all test articles clearly identify the product and provide information<br>adequate to ensure the safe use of the device.<br>Substantial Equivalence: XT-27 and AXS Offset meet the labeling<br>requirements acceptance criteria. | | Intended Use<br>Environment | During the procedure<br>using the bench<br>model, the device was<br>assessed whether it<br>withstood the<br>simulated use<br>conditions. In order<br>to meet acceptance<br>criteria, the evaluating<br>physician/s must state<br>that all test articles<br>can withstand<br>conditions that can<br>typically be seen<br>during use<br>environment of the<br>product. | Intended Use Environment meets acceptance criteria<br>The evaluating physicians confirmed that all Test articles withstand<br>conditions that can typically be seen during use environment of the<br>product.<br>Substantial Equivalence: XT-27 and AXS Offset meet the same<br>intended use environment acceptance criteria. | {12}------------------------------------------------ ## Stryker Neurovascular Premarket Notification, Traditional 510(k) AXS Offset Delivery Assist Catheter {13}------------------------------------------------ ## Stryker Neurovascular Premarket Notification, Traditional 510(k) AXS Offset Delivery Assist Catheter {14}------------------------------------------------ ## Stryker Neurovascular Premarket Notification, Traditional 510(k) AXS Offset Delivery Assist Catheter {15}------------------------------------------------ ### Stryker Neurovascular Premarket Notification, Traditional 510(k) AXS Offset Delivery Assist Catheter | Visibility | The visibility of the<br>tip of the AXS Offset<br>(marker) was assessed<br>using fluoroscopy<br>during delivery to and<br>withdrawal from the<br>intended location in<br>the bench model. In<br>order to meet<br>acceptance criteria,<br>the evaluating<br>physician/s must state<br>that all test articles are<br>visible under<br>fluoroscopy during<br>delivery to and<br>withdrawal from the<br>intended location. | Visibility meets acceptance criteria<br>The evaluating physicians confirmed that all test articles are visible<br>under fluoroscopy during delivery to and withdrawal from the<br>intended location.<br>Substantial Equivalence: XT-27 and AXS Offset meet the same<br>visibility acceptance criteria. | |------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Packaging | Performed packaging<br>visual, dimensional,<br>and performance<br>testing on carton,<br>labels, DFU, and<br>pouch | Packaging visual, dimensional, and performance testing meets the<br>acceptance criteria for all packaging components (carton, labels,<br>DFU, and pouch).<br>Substantial Equivalence: XT-27 and AXS Offset meet the same<br>packaging visual, dimensional, and performance acceptance criteria. | ### Biocompatibility The AXS Offset Delivery Assist Catheter was assessed for impact to biocompatibility. All proposed materials to be used in the AXS Offset Delivery Assist Catheter as per this assessment have a history of safe clinical use throughout the medical device industry and/or within Stryker Neurovascular and have supporting biocompatibility data. The materials used and the manufacturing process used in the AXS Offset Delivery Assist Catheter are the same or very similar to materials used in the cleared reference predicate Transform Occlusion Balloon Catheter (K122576). The history of safe use and supporting biological test data leveraged from for the reference predicate devices noted above, indicates potential exposure to these existing materials at the amounts present under the proposed clinical conditions of use for the AXS Offset Delivery Assist Catheter will be toxicologically insignificant. The minor material and manufacturing differences between the AXS Offset Delivery Assist Catheter and the cleared reference predicate device are considered low risk in terms of impact to the biocompatibility of the AXS Offset Delivery Assist Catheter. Therefore, the supporting Transform Occlusion Balloon Catheter (K122576) biocompatibility test data presented in Transform Occlusion Balloon Catheter Biocompatibility Results Summary Table are applicable to the AXS Offset Delivery Assist Catheter. Although these differences are considered low risk for the biocompatibility of the AXS {16}------------------------------------------------ Offset Delivery Assist Catheter, screening tests were conducted to further provide supporting evidence that these differences do not adversely impact the product. The AXS Offset Delivery Assist Catheter Biocompatibility Results Summary table summarizes the biocompatibility tests that were conducted using the AXS Offset Delivery Assist Catheter. EN ISO 10993 parts are referenced where applicable. | Test | Test Summary | Conclusion | |------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------| | MEM Elution<br>Cytotoxicity/Part 5 | The test article extract<br>showed no evidence of<br>causing cell lysis or toxicity,<br>with a grade of 0 (no<br>reactivity). | Pass.<br>No cytotoxicity or cell lysis.<br>The test article is considered<br>non-cytotoxic. | | Hemolysis Extract/Direct<br>Contact Method/Part 4 | The hemolytic index for the<br>test article in direct contact<br>with blood and for the<br>extractwas <5%. | Pass.<br>Results are considered pass if<br>the hemolytic index of the<br>test article is 5% or less. | | USP Physicochemical<br><661>/Part 18 | The results for the test article<br>were:<br>Non-volatile residue: 7 mg<br>Residue on ignition: < 1 mg<br>Heavy metal: < 1 ppm<br>Buffering capacity: < 1.0 ml | Pass.<br>The test results indicate there<br>are no gross residuals or<br>volatiles. | | FTIR / Part 18 | FTIR scan done to establish<br>baseline for reference only | The baseline identified<br>polyamide type materials<br>which are constituents of the<br>device. | | Natural Rubber Latex | | | | ELISA Inhibition Assay for<br>Antigenic Protein | The test article extract<br>showed no detectable latex. | Pass.<br>Latex below level of<br>detection. | | ASTM D6499-12 | | | | In-vitro Blood Loop Assay<br>with Comparison Article | The test article (AXS DAC)<br>received a worst case score<br>of '1.' And the comparison<br>article (Transform) received<br>a worst case score of '1'<br>where for a score of 0, 1 or 2<br>the test article is deemed<br>thromboresistant. | Pass.<br>Both the test article (AXS<br>DAC) and comparison<br>article (Transform)<br>considered thromboresistant. | | Test | Test Summary | Conclusion | | MEM Elution Cytotoxicity/<br>Part 5 | The test article extract showed<br>no evidence of causing cell<br>lysis or toxicity, with a grade of<br>0 (no reactivity). | Pass.<br>The test article extract met the<br>requirements of the test since the<br>grade was less than a grade 2 (mild<br>reactivity). | | Guinea Pig Maximization<br>Sensitization/Part 10 | The test article showed no<br>evidence of causing delayed<br>dermal contact sensitization. | Pass.<br>The test article is not considered a<br>sensitizer. | | Intracutaneous Reactivity/Part 10 | The difference between test<br>extract mean score and the<br>control mean score was 0.0. | Pass.<br>The test article met the<br>requirements of the test. | | Acute Systemic Injection/Part 11 | There was no mortality or<br>evidence of systemic toxicity. | Pass.<br>The test article met the<br>requirements of the test. | | Materials Mediated Rabbit<br>Pyrogen/Part 11…
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...